Andrew Baum
Stock Analyst at Citigroup
(2.93)
# 1,671
Out of 5,099 analysts
65
Total ratings
76.74%
Success rate
14.42%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $48 → $45 | $50.65 | -11.15% | 13 | Nov 17, 2025 | |
| PFE Pfizer | Maintains: Neutral | $25 → $26 | $25.33 | +2.65% | 11 | Aug 6, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $125 → $115 | $96.89 | +18.69% | 13 | Feb 5, 2025 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $38.09 | +5.01% | 2 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $222.99 | -3.58% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $675 → $895 | $982.22 | -8.88% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $5.56 | +79.86% | 3 | Oct 20, 2023 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $47.27 | - | 2 | Jul 5, 2017 |
Bristol-Myers Squibb Company
Nov 17, 2025
Maintains: Neutral
Price Target: $48 → $45
Current: $50.65
Upside: -11.15%
Pfizer
Aug 6, 2025
Maintains: Neutral
Price Target: $25 → $26
Current: $25.33
Upside: +2.65%
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $125 → $115
Current: $96.89
Upside: +18.69%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $38.09
Upside: +5.01%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $222.99
Upside: -3.58%
Eli Lilly and Company
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $982.22
Upside: -8.88%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $5.56
Upside: +79.86%
GSK plc
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $47.27
Upside: -